Language
Jiangxi Zhonghong Boyuan Biotechnology Co., Ltd. is a national high-tech enterprise with the core business of developing animal models of human diseases (animal modeling, disease animal modeling). The company has successfully developed 300 animal models of human diseases to provide research objects and platforms for CRO efficacy screening, drug metabolism, non-GLP safety evaluation, life science experiments, and transformation of medical scientific and technological achievements
Read more
Guided by the Ministry of Industry and Information Technology and the Ministry of Finance, hosted by the Jiangxi Provincial Department of Industry and Information Technology, the Jiangxi Provincial Department of Finance, and the Office of the Leading...
Read moreIn this season full of hope and challenges, Zhonghong Boyuan has reached an important milestone in its development process - our new laboratory located in Nanchang Economic Development Zone Maker Green Technology Industrial Park has officially been p...
DetailsGuided by the Ministry of Industry and Information Technology and the Ministry of Finance, hosted by the Jiangxi Provincial Department of Industry and Information Technology, the Jiangxi Provincial Department of Finance, and the Office of the Leading...
DetailsOn August 11, 2021, the awarding ceremony of the joint training base for graduate students of Jiangxi University of Traditional Chinese Medicine was officially held in the conference room on the second floor of Jiangxi Zhonghong Boyuan Company! Zhang...
Details
Notice on the prohibition of the use of \"deep cervical lymphatic vessel/node-venous anastomosis\" for the treatment of Alzheimer\'s disease; Notice on the prohibition of the use of \"jejunal ileal anastomosis\" for the treatment ...
Read moreNotice on the prohibition of the use of \"deep cervical lymphatic vessel/node-venous anastomosis\" for the treatment of Alzheimer\'s disease; Notice on the prohibition of the use of \"jejunal ileal anastomosis\" for the treatment ...
DetailsOn July 3, 2025, the China National Medical Products Administration (NMPA) formally approved Eli Lilly\'s terpopeptide (trade name: Mufengda ®) for the treatment of adult obesity combined with moderate to severe obstructive sleep apnea (OSA)...
DetailsShanghai, June 18, 2025 - Shanghai Alis Pharmaceutical Technology Co., Ltd. (stock code: 688578, hereinafter referred to as \"Alis\") announced that its latest approved innovative drug, Arika® (Gerreser citrate tablets) has successfully pre...
DetailsCustomize the most effective experimental programs and animal models for global customers, effectively promote the research and development process of new drugs and new therapies, and provide strong support and services for global drug research and development.
Join Us
